NeoGenomics (NASDAQ:NEO - Get Free Report) has been assigned a $11.00 target price by research analysts at Piper Sandler in a research report issued on Monday, MarketBeat.com reports. The firm currently has an "overweight" rating on the medical research company's stock. Piper Sandler's price target would indicate a potential upside of 95.90% from the company's current price.
Other analysts have also issued reports about the stock. Morgan Stanley set a $8.00 price target on shares of NeoGenomics and gave the stock an "equal weight" rating in a research report on Wednesday, July 30th. Guggenheim initiated coverage on shares of NeoGenomics in a research report on Thursday, May 15th. They issued a "neutral" rating for the company. The Goldman Sachs Group reduced their price target on shares of NeoGenomics from $15.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. BTIG Research reissued a "neutral" rating on shares of NeoGenomics in a research report on Wednesday, July 30th. Finally, Wall Street Zen raised shares of NeoGenomics from a "sell" rating to a "hold" rating in a research report on Tuesday, May 13th. Nine analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $12.75.
Check Out Our Latest Research Report on NeoGenomics
NeoGenomics Price Performance
Shares of NASDAQ:NEO traded down $0.01 during trading hours on Monday, hitting $5.62. 700,863 shares of the company's stock traded hands, compared to its average volume of 1,956,788. NeoGenomics has a 52 week low of $4.72 and a 52 week high of $19.11. The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.58 and a current ratio of 3.92. The company's fifty day simple moving average is $6.95 and its two-hundred day simple moving average is $9.18. The company has a market cap of $725.35 million, a price-to-earnings ratio of -6.98 and a beta of 1.54.
Insider Transactions at NeoGenomics
In related news, Director Lynn A. Tetrault acquired 7,000 shares of the business's stock in a transaction on Friday, May 9th. The stock was bought at an average cost of $8.14 per share, with a total value of $56,980.00. Following the completion of the acquisition, the director owned 7,000 shares in the company, valued at $56,980. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Warren Stone acquired 5,700 shares of the business's stock in a transaction on Monday, May 12th. The shares were bought at an average cost of $8.58 per share, with a total value of $48,906.00. Following the completion of the acquisition, the chief operating officer owned 108,280 shares of the company's stock, valued at approximately $929,042.40. This trade represents a 5.56% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 17,700 shares of company stock worth $143,886. Insiders own 2.40% of the company's stock.
Institutional Trading of NeoGenomics
Several institutional investors and hedge funds have recently added to or reduced their stakes in NEO. Brooklyn Investment Group bought a new position in shares of NeoGenomics during the 1st quarter valued at about $35,000. CWM LLC grew its holdings in NeoGenomics by 42.6% in the 1st quarter. CWM LLC now owns 6,299 shares of the medical research company's stock valued at $60,000 after buying an additional 1,883 shares in the last quarter. AlphaQuest LLC acquired a new stake in shares of NeoGenomics during the 1st quarter worth $60,000. Sterling Capital Management LLC grew its holdings in shares of NeoGenomics by 788.7% during the 4th quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company's stock worth $61,000 after purchasing an additional 3,289 shares in the last quarter. Finally, Moors & Cabot Inc. boosted its stake in NeoGenomics by 20.0% in the second quarter. Moors & Cabot Inc. now owns 12,000 shares of the medical research company's stock valued at $88,000 after buying an additional 2,000 shares in the last quarter. 98.50% of the stock is owned by institutional investors.
NeoGenomics Company Profile
(
Get Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Further Reading
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
